ISSN 2717-7394

Quick Access

Bu Dergi DOI ve Crosscheck üyesidir


Pharmacoeconomic Evaluation Of Trastuzumab Emtansine And Pertuzumab Treatments In Metastatic Breast Cancer Patients

Purpose: We aimed to perform a cost-effectiveness analysis for trastuzumab emtansine (TDM-1) and pertuzumab treatments in patients with HER-2 positive metastatic breast cancer. Method: Patients were detected retrospectively who diagnosed with HER-2 positive metastatic breast cancer and treated with pertuzumab or TDM-1 between 11.2016 - 11.2019 in our hospital. Demographic data, drug doses and periods obtained from the patients' medical records. The evaluated pharmacoeconomic outcomes were quality adjusted life years (QALYs), progression-free survival durations and treatment costs. Results: Treatment with TDM-1 resulted in a mean progression-free survival of 10.5 months. Mean progression-free survival in pertuzumab administered patients was 19 months. In our cost-effectiveness analysis in HER-2 positive metastatic breast cancer resulted in an additional 1.91 life-years gained, at a cost of 69.334 United States Dollars ($) per QALYs in pertuzumab. Also, it was determined an additional 1.75 life-years gained and a cost of 19.255 $ per QALYs in TDM-1. In pertuzumab treatment, progression-free survival was found to be significantly higher compared to TDM-1 (p < 0.001). On the other hand, the cost of this treatment was determined to be approximately 3.5 fold higher than TDM-1. Conclusion: In the study, both treatments were found to be statistically cost-effective. Larger study populations and multi-center studies are needed to more precisely demonstrate the pharmacoeconomic data in this subject.

Trastuzumab emtansine, pertuzumab, breast cancer, cost benefit analysis, cost effectiveness


Advanced Search


    Önemli Duyuru!

    Site üzerinde çalışmalar devam etmektedir.  Sitedeki eksikler en kısa zamanda tamamlanacak.

Address :Yayıncı: Gevher Nesibe Sağlık Araştırmaları Merkezi
Telephone :+90 551 621 70 76 (Turkey) Fax :+90 216 606 32 75

Web Yazılım & Programlama Han Yazılım Bilişim Hizmetleri